Clinical trial
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
NCT00267683 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00267683 |
|---|---|
| Title | Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes |
| Official title | A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | insulin aspart, glibenclamide |
| Enrollment | 9 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Dec 21, 2005 |
| Last update posted | Nov 2, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: